Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immunotherapy shows promise against multiple advanced cancers

NCT ID NCT02908906

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts: first to find the safest dose, then to see how well it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cetrelimab (JNJ-63723283), an immunotherapy drug that helps the immune system attack cancer cells
What this could lead to
If successful, this could provide a new treatment option for several advanced cancers, potentially shrinking tumors and extending life.
What could go wrong
This is an early-phase trial (phase 1/2) with a small number of participants, so the drug may not work for many people. Immunotherapy can cause serious side effects like inflammation in healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer esophageal cancer gastric cancer gastroesophageal cancer Lynch syndrome melanoma neoplasm non-small cell lung carcinoma renal carcinoma small cell lung carcinoma urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

  • Study site

    St Louis, Missouri, United States

  • Study site

    Pittsburgh, Pennsylvania, United States

  • Study site

    Chisinau, Moldova

  • Study site

    Bialystok, Poland

  • Study site

    Warsaw, Poland

  • Study site

    Moscow, Russia

  • Study site

    Pyatigorsk, Russia

  • Study site

    Saint Petersburg, Russia

  • Study site

    Badalona, Spain

  • Study site

    Barcelona, Spain

  • Study site

    Madrid, Spain

  • Study site

    Málaga, Spain

  • Study site

    Pamplona, Spain

  • Study site

    Seville, Spain

  • Study site

    Valencia, Spain

  • Study site

    Gothenburg, Sweden

  • Study site

    Glasgow, United Kingdom

  • Study site

    London, United Kingdom

  • Study site

    Manchester, United Kingdom

  • Study site

    Newcastle upon Tyne, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.